



## **Collaborative Working Project executive summary**

| Project title          | Collaborative working agreement between Sanofi and The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH) to undertake a review of the neuromuscular service   |
|------------------------|--|
| Partner organisation/s |  |
| - a                    | Robert Jones and Agnes Hunt Orthopaedic Hospital,<br>Gobowen, Oswestry SY10 7AG  |
|                        | Sanofi, 410 Thames Valley Park Drive, Reading,<br>Berkshire, RG6 1PT.  |
| Project rationale      | The Robert Jones and Agnes Hunt NHS Orthopaedic  |
|                        | Hospital NHS Foundation Trust (RJAH) is a specialised hospital providing orthopaedic and neuromuscular services, based in Shropshire. The Neuromuscular (NM) service at RJAH provides diagnostic and clinical management services for both children and adults living with neuromuscular conditions.   |
|                        | The neuromuscular service is a major tertiary referral centre for patients with neuromuscular conditions covering Hertfordshire, Warwickshire, Manchester, Liverpool, Shropshire, Midlands, Staffordshire, and Wales, with over 250 new neuromuscular referrals a year. The neuromuscular service plays a vital role in the early diagnosis of patient with neuromuscular conditions, thus any impact on the services can have a delay on neuromuscular patients being effectively diagnosed and referred to a specialist treatment centre. Recent increases in demand and reduction in staff capacity means patients are facing longer waiting times to be seen and to access follow up appointments. |
|                        | The service has identified a number of factors as outlined below which means that a review is required into how the neuromuscular service is currently provided:   |
|                        | <ul> <li>Increase in patient referrals leading to increased demand on the service.</li> <li>No discharge protocol for patients due to nature of condition.</li> <li>Shortage of neuromuscular specialist consultants, physiotherapist, admin, and nursing staff</li> </ul>   |

**Document Number:** MAT-XU-2402372 (v1.0) **Date of Preparation**: June 2024



Document Number: MAT-XU-2402372 (v1.0)



|                    | The service review will help develop an options appraisal to enable them to identify and implement any changes to their current service provision. To do this, the Hospital Trust has requested dedicated project manager support, to work alongside The Trust's own resources, to co-ordinate and deliver on this service review.  |
|--------------------|---|
| Project period     | Q3 2024 Start Date  |
|                    | Q4 2024 End Date  |
| Project objectives | The collaborative working project will deliver the following proposed benefits for Patients, the NHS and Sanofi:  |
|                    | Patients  |
|                    | <ul> <li>Potential reduction in waiting times for patients accessing neuromuscular services.</li> <li>Potential future earlier access for patients to appropriate health care professionals.</li> </ul>   |
|                    | NHS   |
|                    | <ul> <li>Greater clarity of the patient pathway and service to support specific needs of health professionals within RJAH and referring hospital.</li> <li>Review of current service provision and identification of gaps and issues within the neuromuscular Service.</li> <li>Completion of workforce review to inform future service provision.</li> </ul>   |
|                    | Sanofi  |
|                    | <ul> <li>Improved clarity on the pressure points within the service, which will allow Sanofi to develop future strategies within the rare disease area.</li> <li>Improved reputation with the relevant NHS organisations within rare disease.</li> <li>As Sanofi produce medicines in this disease area if overall patient care is optimised there may be an increase in usage of these products in line with local and national guidelines.</li> </ul> |
|                    | This project will be delivered by pooling resources from both parties of indirect funding equivalent to approximately £7000.  |

Date of Preparation: June 2024



Document Number: MAT-XU-2402372 (v1.0)



| Contact details | Sanofi Fleur Chandler, Head of Market Access UK & IE, Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT.  GB-patientaccess@sanofi.com |
|-----------------|---|
|                 | RJAH  Prof Tracey A Willis, Consultant Paediatric Neurologist, Robert Jones and Agnes Hunt Orthopaedic Hospital, Gobowen, Oswestry SY10 7AG           |

Date of Preparation: June 2024